GT Biopharma's market cap is currently ―. The company's EPS TTM is $-5.574; its P/E ratio is -0.74; GT Biopharma is scheduled to report earnings on May 13, 2024, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	-	-	-	-	$ 0.00
Gross Profit	-	-	-	-	-
EBIT	$ -3.48M	$ -1.99M	$ 39.00K	$ -5.86M	$ -6.88M
EBITDA	$ -3.37M	-	$ 64.00K	$ -5.84M	$ -6.88M
Net Income Common Stockholders	$ -2.96M	$ -1.99M	$ 251.00K	$ -5.58M	$ -6.88M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 13.98M	$ 17.97M	$ 19.95M	$ 16.50M	$ 20.78M
Total Assets	$ 14.11M	$ 18.14M	$ 20.13M	$ 16.74M	$ 21.07M
Total Debt	$ 58.00K	$ 120.00K	$ 147.00K	$ 174.00K	$ 198.00K
Net Debt	$ -13.92M	$ -17.85M	$ -19.80M	$ -16.33M	$ -20.59M
Total Liabilities	$ 6.63M	$ 6.38M	$ 7.03M	$ 5.00M	$ 5.12M
Stockholders Equity	$ 7.48M	$ 11.76M	$ 13.05M	$ 11.73M	$ 15.95M
Cash Flow	-
Free Cash Flow	$ -2.05M	-	$ -2.90M	$ -4.30M	$ -2.92M
Operating Cash Flow	$ -2.05M	-	$ -2.90M	$ -4.30M	$ -2.92M
Investing Cash Flow	$ 478.00K	-	$ -6.99M	$ 7.51M	$ 25.00K
Financing Cash Flow	-	-	$ 6.27M	$ -1.00K	$ 0.00

Currency in USD

GT Biopharma Earnings and Revenue History

Income Statement >

GT Biopharma Debt to Assets

Balance Sheet >

GT Biopharma Cash Flow

Cash Flow >

GT Biopharma Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing